The knockdown of IGF2BP1 reduced MDM2 protein levels across ovarian cancer cell lines, regardless of TP53 mutation status, increasing IRF1 and TP53 abundance (Supplementary Fig. S4j). The gene discussed is TP53; the disease is ovarian cancer.